Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy

Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy

Background Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM. Methods Th...

Full description

Saved in:
Bibliographic Details
Main Authors: Sung Hye Kong, Seung Shin Park, Jung Hee Kim, Sang Wan Kim, Se Hyun Kim, Jee Hyun Kim, Chan Soo Shin
Format: Article
Language:English
Published: Korean Endocrine Society 2025-04-01
Series:Endocrinology and Metabolism
Subjects:
calcitonin
denosumab
diphosphonates
hypercalcemia
safety
treatment outcome
Online Access:http://e-enm.org/upload/pdf/enm-2024-2132.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items